Lankhorst Stephanie, Severs David, Markó Lajos, Rakova Natalia, Titze Jens, Müller Dominik N, Danser A H Jan, van den Meiracker Anton H
From the Division of Pharmacology and Vascular Medicine, Department of Internal Medicine (S.L., A.H.J.D., A.H.v.d.M.), Department of Nephrology & Transplantation (D.S.), Erasmus Medical Center, Rotterdam, The Netherlands; Experimental and Clinical Research Center, a Joint Cooperation of Max-Delbrück Center for Molecular Medicine and Charité University Medicine Berlin, Germany (L.M., N.R., D.N.M.); Department of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN (J.T.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (D.N.M.); and Department of Nephrology and Hypertension, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany (N.R.).
Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.
In response to salt loading, Na and Cl accumulate in the skin in excess of water, stimulating skin lymphangiogenesis via activation of the mononuclear phagocyte system cell-derived vascular endothelial growth factor-C-vascular endothelial growth factor type 3 receptor signaling pathway. Inhibition of this pathway results in salt-sensitive hypertension. Sunitinib is an antiangiogenic, anticancer agent that blocks all 3 vascular endothelial growth factor receptors and increases blood pressure. We explored the salt dependency of sunitinib-induced hypertension and whether impairment of skin lymphangiogenesis is an underlying mechanism. Normotensive Wistar-Kyoto rats were exposed to a normal or high salt with or without sunitinib administration. Sunitinib induced a 15 mm Hg rise in telemetrically measured blood pressure, which was aggravated by a high-salt diet (HSD), resulting in a decline of the slope of the pressure-natriuresis curve. Without affecting body weight, plasma Na concentration or renal function, Na and Cl skin content increased by 31% and 32% with the high salt and by 49% and 50% with the HSD plus sunitinib, whereas skin water increased by 17% and 24%, respectively. Skin mononuclear phagocyte system cell density increased both during sunitinib and a HSD, but no further increment was seen when HSD and sunitinib were combined. HSD increased skin lymphangiogenesis, while sunitinib tended to decrease lymphangiogenesis, both during a normal-salt diet and HSD. We conclude that sunitinib induces hypertension that is aggravated by high salt intake and not accompanied by impaired skin lymphangiogenesis.
作为对盐负荷的反应,钠和氯在皮肤中的积累超过了水,通过激活单核吞噬细胞系统细胞衍生的血管内皮生长因子-C-血管内皮生长因子3型受体信号通路刺激皮肤淋巴管生成。抑制该通路会导致盐敏感性高血压。舒尼替尼是一种抗血管生成的抗癌药物,可阻断所有3种血管内皮生长因子受体并升高血压。我们探讨了舒尼替尼诱导的高血压对盐的依赖性,以及皮肤淋巴管生成受损是否是其潜在机制。将血压正常的Wistar-Kyoto大鼠暴露于正常盐或高盐环境中,给予或不给予舒尼替尼。舒尼替尼使遥测血压升高15 mmHg,高盐饮食(HSD)会加重这种情况,导致压力-利钠曲线斜率下降。在不影响体重、血浆钠浓度或肾功能的情况下,高盐组皮肤钠和氯含量分别增加31%和32%,高盐饮食加舒尼替尼组分别增加49%和50%,而皮肤水分分别增加17%和24%。在舒尼替尼治疗期间和高盐饮食期间,皮肤单核吞噬细胞系统细胞密度均增加,但高盐饮食和舒尼替尼联合使用时未见进一步增加。高盐饮食增加皮肤淋巴管生成,而在正常盐饮食和高盐饮食期间,舒尼替尼均倾向于减少淋巴管生成。我们得出结论,舒尼替尼诱导的高血压会因高盐摄入而加重,且不伴有皮肤淋巴管生成受损。